地西他滨逆转肺腺癌厄洛替尼耐药的作用及机制

Effect of decitabine combined with erlotinib on EGFR-TKI resistance in lung adenocarcinoma and its mechanism

目的探讨地西他滨逆转人肺腺癌HCC827/ER细胞厄洛替尼耐药的作用及机制。方法地西他滨、厄洛替尼或联合用药处理HCC827/ER细胞株,MTT法、BrdU、克隆形成实验检测细胞增殖;细胞划痕和Transwell实验检测细胞迁移和侵袭能力;Western blot检测细胞周期相关蛋白表达;DNA甲基化检测laminA/C启动子区甲基化水平。结果地西他滨联合厄洛替尼可明显抑制HCC827/ER细胞增殖,迁移和侵袭能力;抑制laminA/C基因启动子区甲基化水平,促进laminA/C蛋白表达;抑制细胞周期相关蛋白CyclinA2、CyclinB1、CyclinD1、CDK4、CDK6表达,促进p21蛋白上调,阻滞细胞周期。结论地西他滨通过促进laminA/C表达、细胞周期阻滞诱导耐药细胞死亡,逆转肺腺癌HCC827/ER细胞对厄洛替尼的耐药。

Aim To investigate the effect of decitabine combined with erlotinib on EGFR-TKI resistance in lung adenocarcinoma HCC827/ER cells and the underlying mechanism.Methods The HCC827/ER cells were treated with decitabine,erlotinib,or combination of decitabine and erlotinib.MTT assay was used to identify the survival rates of HCC827/ER cells.BrdU assay and colony formation assay were used to detect cell proliferation.Wounding healing and Transwell assay were performed to assess the effects of drugs on cell migration and invasion,respectively.Western blot was used for detecting cell cycle-related proteins.Methylation-Specific PCR was used to analyze the methylation level of promoter of laminA/C.Results Decitabine combined with erlotinib significantly inhibited the proliferation,migration and invasion of HCC827/ER cells.Decitabine reduced the methylation level of laminA/C promoter region and promoted the protein expression of laminA/C.In addition,decitabine combined with erlotinib inhibited the expression of Cyclin A2,Cyclin B1,Cyclin D1,CDK4,CDK6 and promoted P21 overexpression.Conclusions Decitabine reverses erlotinib resistance by promoting laminA/C expression and inducing cell cycle arrest in lung adenocarcinoma HCC827/ER cells.